In the final part of his Pharma Commerce video interview, Philip Sclafani, PwC’s pharmaceutical and life sciences lead, points out that from biosimilars and site-of-care shifts to AI, value-based reimbursement, and potential legislative action, market deflators—not simple cost shifting—will determine whether affordability improves across employer-sponsored plans, Medicaid, and Medicare.
In the third part of his Pharma Commerce video interview, Philip Sclafani, PwC’s pharmaceutical and life sciences lead, explains as medical inflation persists and benefit designs strain under rising drug spend—especially GLP-1s—employers are reaching the limits of what they can absorb, accelerating cost-shifting and fragmenting how employees pay for care.
In the second part of his Pharma Commerce video interview, Philip Sclafani, PwC’s pharmaceutical and life sciences lead, points out that a Medicaid spending tightens and ACA subsidies lapse, reduced public coverage is driving spillover effects—shifting costs to hospitals, employers, and commercial drug pricing in an increasingly interconnected healthcare market.
In the first part of his Pharma Commerce video interview, Philip Sclafani, PwC’s pharmaceutical and life sciences lead, discusses how from GLP-1 adoption to specialty drugs, behavioral health utilization, and hospital consolidation, multiple forces are reshaping employer-sponsored healthcare costs—and pushing premiums and cost-sharing higher.
Published: October 10th 2025 | Updated:
